This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Anti-inflammatory molecules show promise in reducing risks of further heart damage

Anti-inflammatory molecules show promise in reducing risks of further heart damage
Credit: The American Journal of Pathology (2023). DOI: 10.1016/j.ajpath.2023.09.014

Research into the protective effects of two anti-inflammatory molecules following a heart attack has found that two proteins reduce the inflammatory response and scarring within the injured heart. The study is published in The American Journal of Pathology.

Transforming growth factor-beta1 (TGFβ1) and Heligmosomoidespolygyrus TGM (HpTGM) are two molecules found to be beneficial in therapy. Patients with acute heart attacks (ST elevation , or STEMI) are very likely to survive if they undergo timely reopening of the occluded coronary artery (coronary reperfusion) in specialized clinical centers.

However, despite major improvements in treatment, progression to heart failure still represents a major clinical problem.

Correlates with a reduction infarct size after three months

Professor Helen Arthur, Professor of Cardiovascular Biology at Newcastle University, explains, "Coronary reperfusion after STEMI is standard therapy to salvage ischemic heart muscle. However, evidence suggests that the subsequent that the body initiates to repair the damaged heart tissue can also cause further loss of viable heart muscle, and the more muscle that is lost the greater the risk of subsequent progression to heart failure.

"The reason for this study was to investigate the potential protective effects of TGFβ1 as a possible intervention to minimize this additional damage to the heart beyond the ischemic damage caused by the heart attack itself."

The research team found that levels of an important anti-inflammatory protein TGFβ1 in the blood of STEMI patients 24 hours after reperfusion correlated with a reduction in infarct size after three months. To investigate this further they used an established mouse model of a heart attack to test the protective effects of TGFβ1, a protein known to be released in the body in response to tissue injury, and its mimic HpTGM.

This is a protein produced by a to help evade the and thereby enable the worm to live within the tissue lining the gut. Intra-vascular delivery of either of these naturally occurring anti-inflammatory proteins reduced the injurious inflammatory response within the heart and, more importantly, the extent of heart injury, as evidenced by the reduced mature scar size.

The investigators were surprised to find almost identical beneficial effects of TGFβ1 and HpTGM treatment. Although they are both evolutionarily unrelated, both these molecules interact with cells in a similar manner by activating the same signaling pathway. The dose of anti-inflammatory therapy was given at the time of reperfusion, which corresponds to a clinically useful time for a therapeutic intervention in humans.‌

Investigators could attribute the beneficial outcomes to the protective effect of these molecules on (the cells lining the blood vessels that help to regulate the exit of pro-inflammatory white blood cells from the circulation and enter the injured tissue).

TGFβ1 has well-established anti-inflammatory properties, whereas HpTGM is a parasitomimetic with great clinical potential. Recent work in the Maizels lab at the University of Glasgow has also shown that delivery of HpTGM has a major anti-inflammatory effect in mouse models of colitis or airway inflammation, taking advantage of the product evolved by a parasite to quell the immune response to its presence.

Prof Arthur concluded, "The current study shows that exogenous delivery of HpTGM at the time of coronary artery reperfusion dampens the proinflammatory response of coronary endothelial cells and reduces cardiac injury, leading to increased myocardial salvage and reduced scar size, with the corollary of improved prospects for long-term cardiac function.

"The use of HpTGM as an anti-inflammatory therapy in treating heart attack patients is clearly an exciting prospect that requires further translational studies."

More information: Rachael E. Redgrave et al, Exogenous Transforming Growth Factor-β1 and Its Helminth-Derived Mimic Attenuate the Heart's Inflammatory Response to Ischemic Injury and Reduce Mature Scar Size, The American Journal of Pathology (2023). DOI: 10.1016/j.ajpath.2023.09.014

Journal information: American Journal of Pathology
Citation: Anti-inflammatory molecules show promise in reducing risks of further heart damage (2024, March 22) retrieved 22 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Researchers prevent myocardial ischemia/reperfusion injury with oral fullerenes


Feedback to editors